clinical trial · NCT05900531
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers
Kallyope Inc.·phase1·completed·n = 60
ObesityK-757K-757 and open-label sitagliptinMatching placebo to K-757Matching placebo to K-757 and matching placebo to K-833K-757 and K-833Matching placebo to K-757, open-label sitagliptin
brief summary
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 alone, in combination with sitagliptin, or in combination with K-833.
started
Sep 21, 2022
primary completion
May 3, 2023
completion
May 31, 2023
last updated
Nov 22, 2024
official title
A 28-Day Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol